FierceBiotech Radio on the FDA's new boss, Sanofi's latest shortcut, and a little 'financial innovation'

FiercePharma's Eric Palmer and FierceBiotech's Damian Garde discuss the confirmation of Robert Califf as the next FDA commissioner, Sanofi's efforts to undercut Novo Nordisk in diabetes, and a novel approach to regulating drug costs.

Download the episode on iTunes or Stitcher, or listen below--and be sure to subscribe. Let us know what you think by dropping a line to [email protected]

Suggested Articles

Barely two years after paying up $263 million for the ex-Asia rights to BeiGene’s tislelizumab, Celgene is bowing out—to the tune of $150 million.

A University of Pennsylvania team discovered that a protein called TOX helps determine the fate of exhausted T cells in cancer and other diseases.

AstraZeneca is set to spend $630 million on R&D in South Korea over the next five years as part of a wider cooperative agreement.